Another trial, DAPA-CKD enrolled patients 18 years of age or older with an eGFR 25–75, a urine albumin to creatinine ration between 200 and 5,000 mg/g, and who were stable on maximum tolerated ACE inhibitor or ARB with type 2 diabetes (two thirds of patients) or without diabetes. This evidence concerns the gene ALB and chronic kidney disease.